title: A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery.
abstract: This randomized, double-blind study evaluated the relative efficacy of palonosetron (a new, selective 5-hydroxytryptamine type 3 [5-HT(3)] receptor antagonist) and ondansetron in preventing postoperative nausea and vomiting (PONV) in patients undergoing gynaecological laparoscopic surgery. Patients received either palonosetron 0.075 mg (n = 45) or ondansetron 8 mg (n = 45), intravenously, immediately before induction of general anaesthesia. The occurrence of nausea and vomiting and the severity of nausea according to a visual analogue scale were monitored immediately after the end of surgery and during the following 24 h. The incidence of PONV was significantly lower in the palonosetron group compared with the ondansetron group (42.2% vs 66.7%, respectively). There were no significant statistical differences in the visual analogue scale for nausea. In conclusion, palonosetron 0.075 mg was more effective than ondansetron 8 mg in preventing PONV.
authors.forename: S K
authors.initials: SK
authors.lastname: Park
authors.forename: E J
authors.initials: EJ
authors.lastname: Cho
mesh_terms: D000328:Adult; D000758:Anesthesia; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D003710:Demography; D004311:Double-Blind Method; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D010535:Laparoscopy / Q000009:adverse effects*; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D000077924:Palonosetron; D017060:Patient Satisfaction; D020250:Postoperative Nausea and Vomiting / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D011812:Quinuclidines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000932:Antiemetics; D007546:Isoquinolines; D011812:Quinuclidines; D017294:Ondansetron; D000077924:Palonosetron